Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extravascular Hemolysis
Clinical trial NCT06449001 · RECRUITING
Trial details
- NCT number
- NCT06449001
- Sponsor
- Alexion Pharmaceuticals, Inc.
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-08-11
- Primary completion
- 2027-05-28
- Enrollment
- 6
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.